Source: http://nejmqianyan.cn/article/YXQYhpr1713338
Timestamp: 2019-04-19 16:41:18+00:00

Document:
Jonathan J. Darrow, S.J.D., J.D., M.B.A., Jerry Avorn, M.D., and Aaron S. Kesselheim, M.D., J.D., M.P.H.
From the Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston.
1. Pub. L. No. 112-144, 126 Stat. 993 (2012).
2. Fleming T, Sekeres M, Lieberman G, et al. Issue brief: panel 4: development paths for new drugs with large treatment effects seen early. Presented at the Conference on Clinical Cancer Research, Washington, DC, November 10, 2011 (https://www.focr.org/sites/default/files/pdf/Panel4FINAL11411.pdf).
3. McCrimmon KK. ‘Breakthrough’ drugs speed path to cures and the NBA. Health News Colorado. May 15, 2013.
4. Eastman P. FDA’s Breakthrough Therapy designation: update from Janet Woodcock. Oncology Times 2014;36(12):1,18-19 (https://journals.lww.com/oncology-times/Citation/2014/06250/FDA_s_Breakthrough_Therapy_Designation__Update.1.aspx).
5. Continuing America’s leadership: the future of medical innovation for patients — a hearing of the U.S. Senate Committee on Health, Education, Labor, and Pensions, April 28, 2015. Washington, D.C.: Government Publishing Office, 2017 (https://www.gpo.gov/fdsys/pkg/CHRG-114shrg94476/pdf/CHRG-114shrg94476.pdf).
6. Darrow JJ, Avorn J, Kesselheim AS. New FDA breakthrough-drug category — implications for patients. N Engl J Med 2014;370:1252-1258.
7. H.R.Rep. 97-840(I), 1982 U.S.C.C.A.N. 3577 (1982).
8. Food and Drug Administration. Draft guidance for industry: rare diseases: common issues in drug development. August 2015 (https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM458485.pdf).
9. Darrow JJ, Sarpatwari A, Avorn J, Kesselheim AS. Practical, legal, and ethical issues in expanded access to investigational drugs. N Engl J Med 2015;372:279-286.
10. Investigational new drug, antibiotic, and biological drug product regulations; procedures for drugs intended to treat life-threatening and severely debilitating illnesses. Fed Regist 1988;53:41516-41524.
11. New drug, antibiotic, and biological drug product regulations; accelerated approval — FDA: final rule. Fed Regist 1992;57:58942-58960.
12. 21 U.S.C. § 355(d) (2017).
13. Food and Drug Administration. Guidance for industry: expedited programs for serious conditions — drugs and biologics. May 2014 (https://www.fda.gov/downloads/Drugs/Guidances/UCM358301.pdf).
14. Darrow JJ, Kesselheim AS. Drug development and FDA approval, 1938–2013. N Engl J Med 2014;370(26):e39-e39.
15. 21 C.F.R. § 312.87 (1989).
16. FDA Modernization Act, Pub. L. No. 105-115, Sec. 112(a), 111 Stat. 2296, 2310 (1997).
17. Food and Drug Administration. Manual of policies and procedures — good review practice: review of marketing applications for breakthrough therapy-designated drugs and biologics that are receiving an expedited review. March 9, 2015 (https://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ManualofPoliciesProcedures/UCM437281.pdf).
18. Food and Drug Administration. Manual of policies and procedures — good review practice: management of breakthrough therapy-designated drugs and biologics. July 29, 2014 (https://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ManualofPoliciesProcedures/UCM407009.pdf).
19. Food and Drug Administration. Manual of policies and procedures — good review practice: good review management principles and practices for effective IND development and review. April 29, 2013 (https://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ManualofPoliciesProcedures/UCM349907.pdf).
20. Poirier AF, Murphy WR. The impact of Breakthrough Therapy designation on development strategies and timelines for nononcology drugs and vaccines. Clin Pharmacol Ther 2016;100:603-605.
21. Kwok M, Foster T, Steinberg M. Expedited programs for serious conditions: an update on Breakthrough Therapy designation. Clin Ther 2015;37:2104-2120.
22. Hwang TJ, Darrow JJ, Kesselheim AS. The FDA’s expedited programs and clinical development times for novel therapeutics, 2012-2016. JAMA 2017;318:2137-2138.
23. Ross JS, Redberg RF. Would a Breakthrough Therapy by any other name be as promising? JAMA Intern Med 2015;175:1858-1859.
24. Krishnamurti T, Woloshin S, Schwartz LM, Fischhoff B. A randomized trial testing US Food and Drug Administration “breakthrough” language. JAMA Intern Med 2015;175:1856-1858.
25. Abola MV, Prasad V. The use of superlatives in cancer research. JAMA Oncol 2016;2:139-141.
26. Kesselheim AS, Woloshin S, Eddings W, Franklin JM, Ross KM, Schwartz LM. Physicians’ knowledge about FDA approval standards and perceptions of the “Breakthrough Therapy” designation. JAMA 2016;315:1516-1518.
27. McClellan M. Summary and discussion of lessons learned [panel discussion; video at 30:43]. Breakthrough therapy designation: exploring the qualifying criteria. April 24, 2015. Washington, DC: Brookings Institution (https://www.brookings.edu/events/breakthrough-therapy-designation-exploring-the-qualifying-criteria/).
28. Sherman R. Summary and discussion of lessons learned [panel discussion; video at 26:53]. Breakthrough therapy designation: exploring the qualifying criteria. April 24, 2015. Washington, DC: Brookings Institution (https://www.brookings.edu/events/breakthrough-therapy-designation-exploring-the-qualifying-criteria/).
29. Taylor L. US FDA announces first Breakthrough Therapy designations. PharmaTimes. January 9, 2013 (http://www.pharmatimes.com/news/us_fda_announces_first_breakthrough_therapy_designations_1004195).
30. Horning SJ, Haber DA, Selig WK, et al. Developing standards for breakthrough therapy designation in oncology. Clin Cancer Res 2013;19:4297-4304.
31. McClellan M. Breakthrough therapy designation: two and a half years in [panel discussion, video at 3:59]. Breakthrough therapy designation: exploring the qualifying criteria. April 24, 2015. Washington, DC: Brookings Institution (https://www.brookings.edu/events/breakthrough-therapy-designation-exploring-the-qualifying-criteria/).
32. Jenkins J. Breakthrough therapy designation: two and a half years in [panel discussion, video at 20:45]. Breakthrough therapy designation: exploring the qualifying criteria. April. 24, 2015. Washington, DC: Brookings Institution (https://www.brookings.edu/events/breakthrough-therapy-designation-exploring-the-qualifying-criteria/).
33. Food and Drug Administration. Guidance for industry: available therapy. July 2004 (https://www.fda.gov/OHRMS/DOCKETS/98fr/01d-0582-gdl0002.pdf).
34. 21 C.F.R. § 314.510 (2016).
35. Avorn J. Approval of a tuberculosis drug based on a paradoxical surrogate measure. JAMA 2013;309:1349-1350.
36. Kesselheim AS, Avorn J. Approving a problematic muscular dystrophy drug: implications for FDA policy. JAMA 2016;316:2357-2358.
37. Woloshin S, Schwartz LM, White B, Moore TJ. The fate of FDA postapproval studies. N Engl J Med 2017;377:1114-1117.
38. 21 C.F.R. § 314.126 (2016).
39. Food and Drug Administration. Medical review: New Drug Application 208434 (alectinib). November 10, 2015.
40. Food and Drug Administration. Medical review: New Drug Application 205755 (ceritinib). January 21, 2014.
41. Prasad V, Kim C, Burotto M, Vandross A. The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses. JAMA Intern Med 2015;175:1389-1398.
42. Booth CM, Eisenhauer EA. Progression-free survival: meaningful or simply measurable? J Clin Oncol 2012;30:1030-1033.
43. Cherny NI, Sullivan R, Dafni U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015;26:1547-1573.
44. Hey SP, Weijer C. What questions can a placebo answer? Monash Bioeth Rev 2016;34:23-36.
45. Sacks H, Chalmers TC, Smith H Jr. Randomized versus historical controls for clinical trials. Am J Med 1982;72:233-240.
46. Hwang TJ, Carpenter D, Lauffenburger JC, Wang B, Franklin JM, Kesselheim AS. Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Intern Med 2016;176:1826-1833.
47. Darrow JJ, Kesselheim AS. Nearly one-third of new drugs are no better than older drugs, and some are worse. Health Affairs Blog. October 6, 2017 (https://www.healthaffairs.org/do/10.1377/hblog20171021.268271/full/).
48. Pease AM, Krumholz HM, Downing NS, Aminawung JA, Shah ND, Ross JS. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review. BMJ 2017;357:j1680-j1680.
49. Food and Drug Administration. Guidance for industry: clinical trial endpoints for the approval of non-small cell lung cancer drugs and biologics. April 2015 (https://www.fda.gov/downloads/drugs/guidances/ucm259421.pdf).
50. Food and Drug Administration. Medical review: New Drug Application 208261 (elbasvir and grazoprevir). January 15, 2016.
51. Food and Drug Administration. Medical review: New Drug Application 208341 (sofosbuvir and velpatasvir). June 1, 2016.
52. Food and Drug Administration. Office director memo: New Drug Application 022535 (pirfenidone). October 15, 2014.
53. Raghu G, Selman M. Nintedanib and pirfenidone: New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions. Am J Respir Crit Care Med 2015;191:252-254.
54. Spagnolo P. Novel treatments for idiopathic pulmonary fibrosis. Am J Med 2015;128:447-449.
55. Ratner M. Landmark approvals in idiopathic pulmonary fibrosis. Nat Biotechnol 2014;32:1069-1070.
56. Food and Drug Administration. Medical review: New Drug Application 207318 (pimavanserin). February 3, 2016.
57. Food and Drug Administration. Statistical review: New Drug Application 207318 (pimavanserin). February 22, 2016.
58. Food and Drug Administration. Meeting of the Psychopharmacologic Drugs Advisory Committee. March 29, 2016 (https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM502050.pdf).
59. Food and Drug Administration. Office director memorandum: New Drug Application 207318 (pimavanserin). April 29, 2016.
60. Food and Drug Administration. Medical review: New Drug Application 203188 (ivacaftor). November 29, 2011.
61. Food and Drug Administration. Medical review: New Drug Application 206038 (ivacaftor/lumacaftor). June 2, 2015.
62. Food and Drug Administration. Office director memorandum: New Drug Application 206038 (ivacaftor/lumacaftor). July 2, 2015.
63. Becroft DM, Phillips LI, Simmonds A. Hereditary orotic aciduria: long-term therapy with uridine and a trial of uracil. J Pediatr 1969;75:885-891.
64. Food and Drug Administration. Medical review: New Drug Application 208169 (uridine triacetate). September 4, 2015.
65. Darrow JJ. Pharmaceutical efficacy: the illusory legal standard. Wash Lee Law Rev 2013;70:2073-2136.
66. 21 C.F.R. § 314.108(b) (2016).
67. 21 C.F.R. § 316.31(a) (2016).
68. 21 C.F.R. § 314.510 (2016).

References: § 355
 § 312
 V. 
 § 314
 § 314
 § 314
 § 316
 § 314